Halozyme Therapeutics Inc
HALOHealthcare|Biotechnology|USA
$76.19
-2.42 (-3.08%)
DCF (FCF)
$39.38
Earnings Power
$18.42
Upcoming Data Readouts (1)
Mar 2028
Est. completion
P3Hypogonadism, Male
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085n=100
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
NA
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
NCT02921022Aug 2025
P3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399